» Articles » PMID: 30992541

Dronedarone Induces Regression of Coronary Artery Remodeling Related to Better Global Antioxidant Status

Overview
Journal Hypertens Res
Date 2019 Apr 18
PMID 30992541
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Our group previously demonstrated that dronedarone induces regression of left ventricular hypertrophy in spontaneously hypertensive rats (SHRs). We assessed changes in vascular remodeling and oxidative stress following short-term use of this agent. The coronary artery was isolated from 10-month-old male SHRs treated with 100 mg kg dronedarone once daily for 14 days (SHR-D group), and age-matched untreated SHRs were used as hypertensive controls. We analyzed the geometry and composition of the artery and constructed dose-response curves for acetylcholine and serotonin (5-HT). We calculated a global score (OXY-SCORE) from plasma biomarkers of oxidative status: carbonyl levels, thiol levels, reduced glutathione levels, total antioxidant capacity, and superoxide anion scavenging activity. Finally, we analyzed asymmetric dimethylarginine (ADMA) concentrations in plasma. Dronedarone significantly decreased wall thickness (medial and adventitial layer thickness and cell count) and the cross-sectional area of the artery. Dronedarone significantly improved endothelium-dependent relaxation and reduced the contraction induced by 5-HT. The OXY-SCORE was negative in the SHR model group (suggesting an enhanced oxidative status) and was positive in the SHR-D group (suggesting enhanced antioxidant defense). Dronedarone significantly decreased the concentrations of ADMA. We conclude that dronedarone improves coronary artery remodeling in SHRs. The better global antioxidant status after treatment with dronedarone and decreased plasma ADMA levels could contribute to the cardiovascular protective effect of dronedarone.

Citing Articles

OXY-SCORE and Volatile Anesthetics: A New Perspective of Oxidative Stress in EndoVascular Aneurysm Repair-A Randomized Clinical Trial.

Burgos-Santamaria A, Rodriguez-Rodriguez P, Arnalich-Montiel A, Arribas S, Fernandez-Riveira C, Barrio-Perez I Int J Mol Sci. 2024; 25(19).

PMID: 39409100 PMC: 11476523. DOI: 10.3390/ijms251910770.


Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.

Blomstrom-Lundqvist C, Naccarelli G, McKindley D, Bigot G, Wieloch M, Hohnloser S Europace. 2023; 25(3):845-854.

PMID: 36758013 PMC: 10062319. DOI: 10.1093/europace/euad023.


Maintenance over Time of the Effect Produced by Esmolol on the Structure and Function of Coronary Arteries in Hypertensive Heart Diseases.

Martin-Oropesa R, Rodriguez-Rodriguez P, Pazo-Sayos L, Arnalich-Montiel A, Arribas S, Gonzalez M Antioxidants (Basel). 2022; 11(10).

PMID: 36290764 PMC: 9598983. DOI: 10.3390/antiox11102042.


Effect of DrOnedarone on atrial fibrosis progression and atrial fibrillation recurrence postablation: Design of the EDORA randomized clinical trial.

Marrouche N, Dagher L, Wazni O, Akoum N, Mansour M, El Hajjar A J Cardiovasc Electrophysiol. 2021; 32(12):3203-3210.

PMID: 34664772 PMC: 9298087. DOI: 10.1111/jce.15274.


OXY-SCORE: a new perspective for left ventricular hypertrophy diagnosis.

Quintana-Villamandos B, Pazo-Sayos L, Gonzalez Del Pozo I, Rodriguez-Rodriguez P, Bellon J, Pedraz-Prieto A Ther Adv Chronic Dis. 2020; 11:2040622320936417.

PMID: 32647560 PMC: 7328060. DOI: 10.1177/2040622320936417.